Publication

The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice

Arends, S., Veneberg, J. G., Wink, F. R., Bos, R., Brouwer, E., Van Der Veer, E., Bootsma, H., Van Roon, E. N., Maas, F. & Spoorenberg, A., 1-Jun-2016, p. 821-822. 2 p.

Research output: Contribution to conferencePosterAcademic

APA

Arends, S., Veneberg, J. G., Wink, F. R., Bos, R., Brouwer, E., Van Der Veer, E., Bootsma, H., Van Roon, E. N., Maas, F., & Spoorenberg, A. (2016). The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice. 821-822. https://doi.org/10.1136/annrheumdis-2016-eular.3897

Author

Arends, S. ; Veneberg, J.G. ; Wink, F.R. ; Bos, R. ; Brouwer, E. ; Van Der Veer, E. ; Bootsma, H. ; Van Roon, E.N. ; Maas, F. ; Spoorenberg, A. / The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice. 2 p.

Harvard

Arends, S, Veneberg, JG, Wink, FR, Bos, R, Brouwer, E, Van Der Veer, E, Bootsma, H, Van Roon, EN, Maas, F & Spoorenberg, A 2016, 'The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice', pp. 821-822. https://doi.org/10.1136/annrheumdis-2016-eular.3897

Standard

The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice. / Arends, S.; Veneberg, J.G.; Wink, F.R.; Bos, R.; Brouwer, E.; Van Der Veer, E.; Bootsma, H.; Van Roon, E.N.; Maas, F.; Spoorenberg, A.

2016. 821-822.

Research output: Contribution to conferencePosterAcademic

Vancouver

Arends S, Veneberg JG, Wink FR, Bos R, Brouwer E, Van Der Veer E et al. The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice. 2016. https://doi.org/10.1136/annrheumdis-2016-eular.3897


BibTeX

@conference{f53ceca622274437b6ec43e650617ece,
title = "The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice",
abstract = "Background: Ankylosing spondylitis (AS) is not only characterized by excessive bone formation, but also by excessive bone loss which may lead to low bone mineral density (BMD). So far, little is known about the effect of treatment with bisphosphonates on BMD in patients with AS. Objectives: To evaluate the effect of bisphosphonates in combination with calcium/vitamin D supplements on BMD over 2 years in patients with AS stratified for the use of TNF-α inhibitors. Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort, fulfilling the modified New York criteria for AS, who were treated with bisphosphonates and had 2-year follow-up BMD measurements available were included. All patients were treated with bisphosphonates in combination with calcium and/or vitamin D supplements. Alendronate (70 mg/week) and risedronate (35 mg/week) were used most frequently. BMD of the lumbar spine (anterior-posterior projection at L1-L4) and hip (total proximal femur) were measured using DXA. Wilcoxon-signed rank test was used to compare BMD scores at first visit and after 2 years. Analyses were stratified for the use of TNF-α inhibitors. Results: In total, 28 patients were included; 68% were male, 82% HLA-B27+, mean age was 53 ± 14 years, median symptom duration 20 years (range 1-60), and mean BASDAI 5.1±2.5. Fifteen patients (54%) started treatment with bisphosphonates before inclusion in the GLAS cohort (median 3.1 years). Most patients (86%) used bisphosphonates during the entire 2-year follow-up within GLAS. Overall, lumbar spine BMD increased significantly from median Z-score of -0.8 at first visit to -0.3 after 2 years of treatment with bisphosphonates within the GLAS cohort. Hip BMD increased significantly from -1.1 at first visit to -0.9 after 2 years. In the 10 patients not using TNF-α inhibitors, only lumbar spine BMD increased significantly after 2 years of treatment. In the 14 patients starting TNF-α inhibitors, lumbar spine and hip BMD increased significantly after 2 years. The remaining 4 patients already used TNF-α inhibitors (Table 1). Comparable results were found for BMD T-scores. Conclusions: In our observational cohort study, lumbar spine BMD improved significantly after 2 years of follow-up in all AS patients treated with bisphosphonates. This improvement was most pronounced in patients starting TNF-α inhibitors. Hip BMD only improved significantly in patients also starting TNF-α inhibitors. (Table Presented).",
keywords = "alendronic acid, calcium, endogenous compound, HLA B27 antigen, risedronic acid, tumor necrosis factor inhibitor, vitamin D, adult, Bath ankylosing spondylitis disease activity index, bone density, clinical article, clinical practice, clinical trial, cohort analysis, controlled study, drug combination, drug therapy, female, follow up, hip, human, lumbar spine, male, middle aged, New York, pelvic girdle, proximal femur, symptom, Wilcoxon signed ranks test",
author = "S. Arends and J.G. Veneberg and F.R. Wink and R. Bos and E. Brouwer and {Van Der Veer}, E. and H. Bootsma and {Van Roon}, E.N. and F. Maas and A. Spoorenberg",
year = "2016",
month = jun,
day = "1",
doi = "10.1136/annrheumdis-2016-eular.3897",
language = "English",
pages = "821--822",

}

RIS

TY - CONF

T1 - The effect of bisphosphonates on bone mineral density in patients with ankylosing spondylitis in daily clinical practice

AU - Arends, S.

AU - Veneberg, J.G.

AU - Wink, F.R.

AU - Bos, R.

AU - Brouwer, E.

AU - Van Der Veer, E.

AU - Bootsma, H.

AU - Van Roon, E.N.

AU - Maas, F.

AU - Spoorenberg, A.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Ankylosing spondylitis (AS) is not only characterized by excessive bone formation, but also by excessive bone loss which may lead to low bone mineral density (BMD). So far, little is known about the effect of treatment with bisphosphonates on BMD in patients with AS. Objectives: To evaluate the effect of bisphosphonates in combination with calcium/vitamin D supplements on BMD over 2 years in patients with AS stratified for the use of TNF-α inhibitors. Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort, fulfilling the modified New York criteria for AS, who were treated with bisphosphonates and had 2-year follow-up BMD measurements available were included. All patients were treated with bisphosphonates in combination with calcium and/or vitamin D supplements. Alendronate (70 mg/week) and risedronate (35 mg/week) were used most frequently. BMD of the lumbar spine (anterior-posterior projection at L1-L4) and hip (total proximal femur) were measured using DXA. Wilcoxon-signed rank test was used to compare BMD scores at first visit and after 2 years. Analyses were stratified for the use of TNF-α inhibitors. Results: In total, 28 patients were included; 68% were male, 82% HLA-B27+, mean age was 53 ± 14 years, median symptom duration 20 years (range 1-60), and mean BASDAI 5.1±2.5. Fifteen patients (54%) started treatment with bisphosphonates before inclusion in the GLAS cohort (median 3.1 years). Most patients (86%) used bisphosphonates during the entire 2-year follow-up within GLAS. Overall, lumbar spine BMD increased significantly from median Z-score of -0.8 at first visit to -0.3 after 2 years of treatment with bisphosphonates within the GLAS cohort. Hip BMD increased significantly from -1.1 at first visit to -0.9 after 2 years. In the 10 patients not using TNF-α inhibitors, only lumbar spine BMD increased significantly after 2 years of treatment. In the 14 patients starting TNF-α inhibitors, lumbar spine and hip BMD increased significantly after 2 years. The remaining 4 patients already used TNF-α inhibitors (Table 1). Comparable results were found for BMD T-scores. Conclusions: In our observational cohort study, lumbar spine BMD improved significantly after 2 years of follow-up in all AS patients treated with bisphosphonates. This improvement was most pronounced in patients starting TNF-α inhibitors. Hip BMD only improved significantly in patients also starting TNF-α inhibitors. (Table Presented).

AB - Background: Ankylosing spondylitis (AS) is not only characterized by excessive bone formation, but also by excessive bone loss which may lead to low bone mineral density (BMD). So far, little is known about the effect of treatment with bisphosphonates on BMD in patients with AS. Objectives: To evaluate the effect of bisphosphonates in combination with calcium/vitamin D supplements on BMD over 2 years in patients with AS stratified for the use of TNF-α inhibitors. Methods: Patients from the Groningen Leeuwarden AS (GLAS) cohort, fulfilling the modified New York criteria for AS, who were treated with bisphosphonates and had 2-year follow-up BMD measurements available were included. All patients were treated with bisphosphonates in combination with calcium and/or vitamin D supplements. Alendronate (70 mg/week) and risedronate (35 mg/week) were used most frequently. BMD of the lumbar spine (anterior-posterior projection at L1-L4) and hip (total proximal femur) were measured using DXA. Wilcoxon-signed rank test was used to compare BMD scores at first visit and after 2 years. Analyses were stratified for the use of TNF-α inhibitors. Results: In total, 28 patients were included; 68% were male, 82% HLA-B27+, mean age was 53 ± 14 years, median symptom duration 20 years (range 1-60), and mean BASDAI 5.1±2.5. Fifteen patients (54%) started treatment with bisphosphonates before inclusion in the GLAS cohort (median 3.1 years). Most patients (86%) used bisphosphonates during the entire 2-year follow-up within GLAS. Overall, lumbar spine BMD increased significantly from median Z-score of -0.8 at first visit to -0.3 after 2 years of treatment with bisphosphonates within the GLAS cohort. Hip BMD increased significantly from -1.1 at first visit to -0.9 after 2 years. In the 10 patients not using TNF-α inhibitors, only lumbar spine BMD increased significantly after 2 years of treatment. In the 14 patients starting TNF-α inhibitors, lumbar spine and hip BMD increased significantly after 2 years. The remaining 4 patients already used TNF-α inhibitors (Table 1). Comparable results were found for BMD T-scores. Conclusions: In our observational cohort study, lumbar spine BMD improved significantly after 2 years of follow-up in all AS patients treated with bisphosphonates. This improvement was most pronounced in patients starting TNF-α inhibitors. Hip BMD only improved significantly in patients also starting TNF-α inhibitors. (Table Presented).

KW - alendronic acid

KW - calcium

KW - endogenous compound

KW - HLA B27 antigen

KW - risedronic acid

KW - tumor necrosis factor inhibitor

KW - vitamin D

KW - adult

KW - Bath ankylosing spondylitis disease activity index

KW - bone density

KW - clinical article

KW - clinical practice

KW - clinical trial

KW - cohort analysis

KW - controlled study

KW - drug combination

KW - drug therapy

KW - female

KW - follow up

KW - hip

KW - human

KW - lumbar spine

KW - male

KW - middle aged

KW - New York

KW - pelvic girdle

KW - proximal femur

KW - symptom

KW - Wilcoxon signed ranks test

U2 - 10.1136/annrheumdis-2016-eular.3897

DO - 10.1136/annrheumdis-2016-eular.3897

M3 - Poster

SP - 821

EP - 822

ER -

ID: 50385361